Additionally, in the trial examining alcohol use disorder, a significant reduction in alcohol consumption was observed only in a specific subgroup of patients with obesity, suggesting that patient characteristics, such as BMI, might influence treatment outcomes
doi: 10.1038/sj.bjp.0705964 186 BarakNGreenwayFLFujiokaKAronneLJKushnerRF
Hindbrain melanocortin 3/4 receptors modulate the food intake and body weight suppressive effects of the GLP-1 receptor agonist, liraglutide
Survodutide is a novel dual-action drug designed to treat obesity and related metabolic conditions
Glucocorticoids, commonly employed as first-line treatment of irAEs, do not affect certain toxicities, and high doses may negatively affect outcomes (122, 231234)